Global Patent Index - EP 3442532 A4

EP 3442532 A4 20191211 - TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS

Title (en)

TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS

Title (de)

BEHANDLUNG EINES NIERENZELLKARZINOMS MIT LENVATINIB UND EVEROLIMUS

Title (fr)

TRAITEMENT DU CARCINOME À CELLULES RÉNALES À L'AIDE DE LENVATINIB ET D'ÉVÉROLIMUS

Publication

EP 3442532 A4 20191211 (EN)

Application

EP 17782552 A 20170417

Priority

  • JP 2016081787 A 20160415
  • US 201662322916 P 20160415
  • JP 2017015461 W 20170417

Abstract (en)

[origin: WO2017179739A1] Methods and compositions for treating a renal cell carcinoma with the combination of lenvatinib or a pharmaceutically acceptable salt thereof and everolimus are provided. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.

IPC 8 full level

A61K 31/47 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/436 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP KR)

A61K 9/0053 (2013.01 - KR); A61K 31/436 (2013.01 - EP KR); A61K 31/47 (2013.01 - EP KR); A61K 45/06 (2013.01 - EP KR); A61P 35/00 (2018.01 - EP KR); A61K 2300/00 (2013.01 - KR)

C-Set (source: EP)

  1. A61K 31/436 + A61K 2300/00
  2. A61K 31/47 + A61K 2300/00

Citation (search report)

No further relevant documents disclosed

Citation (examination)

  • LEONETTI ALESSANDRO ET AL: "Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma", SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN THE TREATMENT OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE., vol. Volume 13, 1 June 2017 (2017-06-01), pages 799 - 806, XP093107244, ISSN: 1178-203X, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=37200> DOI: 10.2147/TCRM.S126910
  • PAL SUMANTA K ET AL: "Phase 2 trial of Ienvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)", THE 19TH ANNUAL MEETING OF THE INTERNATIONAL KIDNEY CANCER SYMPOSIUM, 1 December 2020 (2020-12-01), pages 31 - 35, XP093107604, Retrieved from the Internet <URL:https://www.kidneycancer.org/wp-content/uploads/2022/11/IKCS20-Abstract-Supplement_KidneyCancerJournal.pdf> [retrieved on 20231130]
  • EISAI: "EISAI ANNOUNCES NEW INVESTIGATIONAL DATA EVALUATING TKIMTOR INHIBITOR REGIMEN LENVIMA (LENVATINIB) PLUS EVEROLIMUS IN ADVANCED RENAL CELL CARCINOMA (RCC) AT IKCS", HUMAN HEALTH CARE, 7 November 2020 (2020-11-07), XP093107608, Retrieved from the Internet <URL:https://media-us.eisai.com/2020-11-07-Eisai-Announces-New-Investigational-Data-Evaluating-TKI-mTOR-Inhibitor-Regimen-LENVIMA-R-lenvatinib-Plus-Everolimus-in-Advanced-Renal-Cell-Carcinoma-RCC-at-IKCS-2020> [retrieved on 20231130]
  • EISAI GMBH: "summary of product characteristics", 16 May 2021 (2021-05-16), pages 1 - 43, XP093107850, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/kisplyx-epar-product-information_en.pdf>
  • See also references of WO 2017179739A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017179739 A1 20171019; AU 2017249459 A1 20181025; CA 3019682 A1 20171019; CN 108883106 A 20181123; EP 3442532 A1 20190220; EP 3442532 A4 20191211; KR 20180129795 A 20181205; SG 11201808774R A 20181129

DOCDB simple family (application)

JP 2017015461 W 20170417; AU 2017249459 A 20170417; CA 3019682 A 20170417; CN 201780020786 A 20170417; EP 17782552 A 20170417; KR 20187028053 A 20170417; SG 11201808774R A 20170417